In a significant policy move, the U.K. government announced the indefinite prohibition of puberty blockers for teenagers dealing with gender dysphoria, except in clinical trial settings.
U.K. Puts Indefinite Halt on Puberty Blockers for Minors
U.K. Puts Indefinite Halt on Puberty Blockers for Minors
The British government bans the use of puberty blockers for youth under 18, due to safety concerns.
The government’s decision, which follows earlier temporary restrictions, was confirmed by Health Secretary Wes Streeting on December 11, 2024. He stated that this action is based on expert medical advice indicating serious safety risks associated with the administration of puberty blockers without thorough research on their effects. “It is crucial we exercise caution and prioritize the safety of this vulnerable demographic,” Streeting noted. The government's ban will extend across England, Scotland, Wales, and Northern Ireland.
This decision aligns with steps taken by the prior Conservative administration to limit the prescribing of hormone treatments intended to manage gender dysphoria. The National Health Service (NHS) halted routine prescriptions of puberty blockers for individuals under 18 after a crucial review conducted by pediatrician Hilary Cass. Her April report questioned the current standards of gender identity treatments, stating they were based on “shaky foundations,” particularly concerning the evidence for administering drugs to pause puberty or alter physical traits.
Looking ahead, the government plans to initiate a clinical trial next year to build a solid evidence base regarding the use of puberty blockers in treating gender dysphoria. This trial aims to ensure that any future medical treatments are backed by robust scientific understanding, ensuring the wellbeing of young people navigating through these complex issues.
This decision aligns with steps taken by the prior Conservative administration to limit the prescribing of hormone treatments intended to manage gender dysphoria. The National Health Service (NHS) halted routine prescriptions of puberty blockers for individuals under 18 after a crucial review conducted by pediatrician Hilary Cass. Her April report questioned the current standards of gender identity treatments, stating they were based on “shaky foundations,” particularly concerning the evidence for administering drugs to pause puberty or alter physical traits.
Looking ahead, the government plans to initiate a clinical trial next year to build a solid evidence base regarding the use of puberty blockers in treating gender dysphoria. This trial aims to ensure that any future medical treatments are backed by robust scientific understanding, ensuring the wellbeing of young people navigating through these complex issues.
